Pyoderma gangrenosum
Pyoderma gangrenosum waa cudur maqaarka barar ah oo naadir ah halkaas oo malax ama qanjidhada xanuunka ay noqdaan boogo si tartiib tartiib ah u koraya. Pyoderma gangrenosum ma aha mid faafa. Daaweynta waxaa ku jiri kara corticosteroids, cyclosporin, ama unugyada difaaca jirka ee monoclonal ee kala duwan. In kasta oo ay saameyn karto dadka da 'kasta leh, waxay inta badan saamaysaa dadka da'doodu tahay 40-ka iyo 50-ka.
☆ Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Lugta qofka qaba ulcerative colitis.
References
Pyoderma gangrenosum waa xaalad maqaarka ah oo naadir ah oo keenta boogo xanuun leh oo leh geeso guduudan ama guduudan. Waxaa loo kala saaraa sida cudur barar ah oo waa qayb ka mid ah kooxda loo yaqaanno dermatoses neutrophilic. Sababta pyoderma gangrenosum waa mid adag, oo ku lug leh dhibaatooyin la xiriira difaaca gudaha iyo la qabsiga labadaba ee dadka hidde ahaan u nugul. Dhawaan, cilmi-baarayaashu waxay diiradda saareen timaha follicule sida barta suurtagalka ah ee bilawga cudurka.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum waa xaalad maqaarka ah oo naadir ah oo keenta boogo aad u xanuun badan. In kasta oo aynaan si buuxda u fahmin sababteeda, waxaan ognahay inay ku lug leedahay kordhinta dhaqdhaqaaqa unugyada difaaca qaarkood. Daawaynta cudurka weli ma fududa. Waxaan haynaa daawooyin kala duwan oo xakameynaya habka difaaca jirka ama wax ka beddelaya dhaqdhaqaaqiisa. Kuwaas waxaa barbar socda, waxaan sidoo kale diiradda saareynaa daawaynta boogaha iyo maaraynta xanuunka. Corticosteroids iyo cyclosporine ayaa inta badan ah doorashada koowaad ee daaweynta, laakiin waayadan dambe, waxaa jiray cilmi baaris dheeraad ah oo ku saabsan isticmaalka daawaynta bayoolojiga sida TNF-α inhibitors. Bayoolojiyadan si sii kordheysa ayaa loo doorbidaa, gaar ahaan bukaanada qaba xaaladaha kale ee bararka, waxaana hore loo isticmaalay habka cudurka.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
